Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin's lymphoma.

Tsirigotis, Panagiotis

Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin's lymphoma. [electronic resource] - Annals of hematology Mar 2010 - 263-72 p. digital

Publication Type: Clinical Trial; Journal Article

1432-0584

10.1007/s00277-009-0808-5 doi


Adolescent
Adult
Aged
Antibodies, Monoclonal--administration & dosage
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Combined Modality Therapy
Female
Hematopoietic Stem Cell Transplantation--methods
Humans
Lymphoma, B-Cell--mortality
Male
Middle Aged
Remission Induction
Rituximab
Secondary Prevention
Survival Analysis
Transplantation, Autologous
Treatment Outcome
Young Adult